NJ State Employees Deferred Compensation Plan’s Pacific Biosciences PACB Stock Holding History

NJ State Employees Deferred Compensation Plan’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$128K	–	288
2025 Q3	$128K	Hold	100,000	–	–	0.01%	418
2025 Q2	$124K	Hold	100,000	–	–	0.01%	414
2025 Q1	$118K	Hold	100,000	–	–	0.02%	418
2024 Q4	$183K	Hold	100,000	–	–	0.02%	428
2024 Q3	$170K	Hold	100,000	–	–	0.02%	442
2024 Q2	$137K	Hold	100,000	–	–	0.02%	443
2024 Q1	$375K	Hold	100,000	–	–	0.05%	337
2023 Q4	$981K	Hold	100,000	–	–	0.14%	176
2023 Q3	$835K	Hold	100,000	–	–	0.13%	178
2023 Q2	$1.33M	Hold	100,000	–	–	0.19%	123
2023 Q1	$1.16M	Hold	100,000	–	–	0.18%	133
2022 Q4	$818K	Hold	100,000	–	–	0.13%	171
2022 Q3	$581K	Hold	100,000	–	–	0.1%	216
2022 Q2	$442K	Hold	100,000	–	–	0.07%	278
2022 Q1	$910K	Hold	100,000	–	–	0.12%	175
2021 Q4	$2.05M	Hold	100,000	–	–	0.26%	97
2021 Q3	$2.56M	Hold	100,000	–	–	0.35%	77
2021 Q2	$3.5M	Hold	100,000	–	–	0.46%	50
2021 Q1	$3.33M	Hold	100,000	–	–	0.47%	48
2020 Q4	$2.59M	Hold	100,000	–	–	0.4%	65
2020 Q3	$987K	Hold	100,000	–	–	0.18%	117
2020 Q2	$345K	Hold	100,000	–	–	0.06%	288
2020 Q1	$306K	Hold	100,000	–	–	0.07%	280
2019 Q4	$514K	Hold	100,000	–	–	0.09%	263
2019 Q3	$516K	Hold	100,000	–	–	0.09%	237
2019 Q2	$605K	Buy	100,000 +20,000	+25%	+$140K	0.11%	191
2019 Q1	$578K	Buy	80,000 +30,000	+60%	+$217K	0.11%	208
2018 Q4	$370K	Buy	+50,000	New	+$317K	0.08%	314

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

NJ State Employees Deferred Compensation Plan's PACB Position: Q4 2025 in Review

NJ State Employees Deferred Compensation Plan sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 100,000 shares — an estimated $128K sold.

NJ State Employees Deferred Compensation Plan first reported a position in PACB in Q4 2018 and held it in 28 quarters. The position peaked at $3.5M in Q2 2021. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

NJ State Employees Deferred Compensation Plan reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
NJ State Employees Deferred Compensation Plan sold 100,000 Pacific Biosciences shares in Q4 2025, an estimated $128K.
NJ State Employees Deferred Compensation Plan first reported a position in Pacific Biosciences in Q4 2018 and held it in 28 quarters.
NJ State Employees Deferred Compensation Plan's Pacific Biosciences position peaked at $3.5M in Q2 2021.
215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on NJ State Employees Deferred Compensation Plan's 13F filing for Q4 2025.